05.07.2016
Evonik Industries AG DE000EVNK013
DGAP-News: Evonik Industries AG: Evonik acquires NOREL's probiotics business
DGAP-News: Evonik Industries AG / Key word(s): Takeover
Evonik Industries AG: Evonik acquires NOREL's probiotics business
05.07.2016 / 10:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Evonik acquires NOREL's probiotics business
Essen. Evonik signed a purchase agreement on July 4, 2016, for acquisition
of the probiotics business of the Spanish company NOREL, a global supplier
of animal feed ingredients. The agreement sees Evonik acquiring NOREL's
probiotics product portfolio as well as the company's site in León (Spain).
The business will be integrated into Evonik's Animal Nutrition Business
Line. The parties have agreed not to disclose details of the transaction.
Evonik is currently expanding its portfolio of sustainable and healthy
solutions in the field of animal nutrition and striving to provide
innovative solutions for antibiotic-free livestock management. Food safety
and quality are increasingly important to end consumers. "There is great
awareness for the relevance of animal feed quality for sustainable
livestock management, as it influences both animal and human health," says
Dr. Emmanuel Auer, head of the Animal Nutrition Business Line of Evonik.
For Evonik, probiotics play a key role as a possible alternative to the use
of antibiotics and antibiotic growth promotors. Probiotics are living
microorganisms and have a positive effect on the gastro-enteric system of
animals, as scientific studies have shown. In particular, they play a key
role in maintaining the gut health of animals. The full benefits of
probiotics as well as their potential positive impact in other health
areas, however, have not yet been fully exploited.
"For us, this acquisition marks an important step into the probiotics
market. By combining the technologies of NOREL and Evonik we can create a
platform for the development of new customer solutions, which are built
around probiotics product families and application services," says Auer.
"We want to position Evonik as an innovative solution provider in the field
of antibiotic-free livestock management". NOREL's portfolio includes a
range of probiotic products for application in poultry and pigs, as well as
in aquaculture, and whose effects have been scientifically proven.
"For the last 25 years we have worked on probiotic products and taken these
from their development stage straight through to commercialization.
Products such as Ecobiol and Fecinor are already available in many markets.
"That's something we're very proud of, and we are pleased that our
probiotics business has found a new home and future within Evonik", says
Francisco Moral, managing director of NOREL.
NOREL's probiotics business gives Evonik access to this product range and
to more than 20 markets including the European market. "Our aim is to be
able to provide the most comprehensive and effective solutions possible in
the field of animal nutrition in order to contribute to the sustainable
nutrition of a growing world population", stresses Auer.
With more than 60 years of experience in the production of essential amino
acids, Evonik offers solutions for efficient and sustainable animal
nutrition to customers in more than a hundred countries around the world.
By extending its product range beyond amino acids to include innovative
feed additives, Evonik plans to contribute even further to the efficiency
of animal feed and to create additional value for its customers. Evonik
products and services in the area of animal nutrition play a key role
globally in healthy and affordable feed production that conserves natural
resources and reduces the carbon footprint.
Company information
Evonik, the creative industrial group from Germany, is one of the world
leaders
in specialty chemicals. Profitable growth and a sustained increase in the
value of the company form the heart of Evonik's corporate strategy. Its
activities focus on the key megatrends health, nutrition, resource
efficiency and globalization. Evonik benefits specifically from its
innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2015
more than 33,500 employees generated sales of around EUR13.5 billion and an
operating profit (adjusted EBITDA) of about EUR2.47 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and
contributes to fulfilling basic human needs. That includes applications for
everyday consumer goods as well as animal nutrition and health care. This
segment employed about 7,000 employees, and generated sales of around
EUR4.9 billion in 2015.
About NOREL
NOREL is a Spanish company whose business is the development, manufacturing
and trading of additives and raw materials for animal nutrition (aquatic
and terrestrial species). NOREL has more than 30 years of experience and is
present in more than 70 countries around the world. It develops innovative
and practical products as a result of a strong relation with customers and
this research approach. These facts position NOREL as one of the leading
companies of feed additives worldwide.
Disclaimer
In so far as forecasts or expectations are expressed in this Investor
Relations News or where our statements concern the future, these forecasts,
expectations or statements may involve known or unknown risks and
uncertainties. Actual results or developments may vary, depending on
changes in the operating environment. Neither Evonik Industries AG nor its
group companies assume an obligation to update the forecasts, expectations
or statements contained in this release.
Contact:
Tim Lange
Head of Investor Relations
Phone +49 201 177-3150
[email protected]
Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Telefax +49 201 177-3475
www.evonik.com
Supervisory Board
Dr. Werner Müller, Chairman
Executive Board
Dr. Klaus Engel, Chairman
Christian Kullmann, Deputy Chairman
Dr. Ralph Sven Kaufmann
Thomas Wessel
Ute Wolf
Registered office Essen
Registered court
Essen local court
Commercial registry B 19474
VAT ID no. DE 811160003
---------------------------------------------------------------------------
05.07.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone: +49 (0) 201 177-01
Fax: +49 (0) 201 177-3475
E-mail: [email protected]
Internet: www.evonik.com
ISIN: DE000EVNK013, XS0911405784
WKN: EVNK01, A1TM7T
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Hamburg, Hanover, Munich,
Stuttgart; Terminbörse EUREX; Luxemburg
End of News DGAP News Service
---------------------------------------------------------------------------
477915 05.07.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evonik Industries AG ISIN: DE000EVNK013 können Sie bei EQS abrufen
Chemie , EVNK01 , EVK , XETR:EVK